TABLE 3.
Univariate and multivariate analysis for PFS and OS in metastatic breast cancer patients (n = 64).
Univariate analysis | ||||
---|---|---|---|---|
Cox regression | PFS | OS | ||
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Age (<63 vs ≥ 63) | 1.46 (0.867–2.458) | 0.155 | 1.169 (0.680–2.010) | 0.572 |
Menopausal status (pre vs post) | 1.049 (0.624–1.734) | 0.879 | 1.063 (0.606–1.865) | 0.830 |
PS (2–3 vs 0–1) | 1.723 (0.933–3.182) | 0.082 | 2.031 (1.069–3.860) | 0.030* |
Disease status (recurrent vs de novo) | 2.544 (1.412–4.584) | 0.002* | 1.389 (0.778–2.481) | 0.266 |
Grade (III vs I/II) | 1.352 (0.800–2.283) | 0.260 | 1.597 (0.898–2.840) | 0.111 |
ER status (negative vs positive) | 1.023 (0.546–1.916) | 0.944 | 1.178 (0.619–2.243) | 0.618 |
PR status (negative vs positive) | 1.389 (0.798–2.418) | 0.245 | 1.120 (0.623–2.011) | 0.705 |
HER2 (positive vs negative) | 1.020 (0.575–1.810) | 0.946 | 1.010 (0.548–1.862) | 0.975 |
Visceral metastasis (yes vs no) | 1.485 (0.699–3.153) | 0.304 | 1.143 (0.537–2.436) | 0.729 |
Non visceral metastasis (yes vs no) | 1.064 (0.536–2.112) | 0.859 | 1.421 (0.669–3.020) | 0.361 |
miR-10b (low vs high) | 1.845 (1.087–3.131) | 0.023* | 1.756 (1.010–3.082) | 0.046* |
miR-19a (low vs high) | 1.431 (0.865–2.369) | 0.163 | 1.180 (0.688–2.024) | 0.548 |
miR-20a (low vs high) | 1.367 (0.826–2.262) | 0.224 | 1.475 (0.860–2.529) | 0.158 |
miR-126 (low vs high) | 1.211 (0.735–1.995) | 0.453 | 1.254 (0.731–2.151) | 0.411 |
miR-155 (low vs high) | 1.437 (0.868–2.379) | 0.158 | 1.320 (0.760–2.263) | 0.314 |
Multivariate analysis | ||||
PS (2–3 vs 0–1) | 2.031 (1.069–3.860) | 0.03* | ||
Disease status (recurrent vs de novo) | 2.657 (1.462–4.831) | 0.001* | ||
miR-10b (low vs high) | 1.920 (1.126–3.273) | 0.017* |
PFS, progression free survival; OS, overall survival; HR, hazard ratio; CI, confidence intervals; PS, performance status; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor; *p < 0.05.